<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300365</url>
  </required_header>
  <id_info>
    <org_study_id>803751</org_study_id>
    <secondary_id>Pionir</secondary_id>
    <nct_id>NCT00300365</nct_id>
  </id_info>
  <brief_title>Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled Trial of Pioglitazone and Niacin Extended Release in Non-diabetic Patients With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kos Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <brief_summary>
    <textblock>
      We will test our primary hypothesis that combining niacin extended release (niacin-ER), at a
      daily dosage of up to 2.0 g with pioglitazone, at a daily dosage of 45 mg will result in a
      12% greater increase in HDL-C when compared to niacin-ER monotherapy over 12 weeks in
      non-diabetic patients with the metabolic syndrome (see Table 1).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-arm, parallel, double-blind randomized prospective clinical trial. The subjects
      will be asked to provide informed consent, and then undergo screening for enrollment criteria
      at the first visit (-5 weeks). The subjects who are eligible, and provide informed consent
      will return for Visit 2 baseline data (-4 weeks), and then begin the unblinded niacin-ER
      titration. Specifically, subjects will receive a starting dose of niacin-ER of 500 mg per
      day, which will be increased in 500 mg increments every week up to a dose of 2000 mg per day.
      Subjects will need to tolerate at least 1500 mg per day of niacin-ER in order to remain in
      the study and be randomized. Thus subjects who are unable to tolerate the 2000 mg daily dose
      of niacin-ER will be taken back to 1500 mg per day for one week and then randomized. Subjects
      who develop prohibitive side effects at doses less than 1500 mg per day will be discontinued
      from the study. All subjects who are able to take the target dose of niacin-ER will continue
      that dose of niacin-ER and come to the General Clinical Research Center (GCRC) to be
      randomized in a 1:1 fashion to either niacin-ER plus pioglitazone or niacin-ER plus matching
      placebo for 12 weeks. Pioglitazone will be started at 30 mg and then increased to 45 mg at
      week 6. This entry design is designed to minimize the differences in mean dose of niacin-ER
      and dropout rate between study groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Pioglitazone and placebo were overencapsulated</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Increase in High Density Lipoprotein Cholesterol (HDL-C) at Baseline and 12 Weeks</measure>
    <time_frame>Baseline, after 12 weeks of pioglitazone vs placebo</time_frame>
    <description>Mean increase in HDL-C from baseline (week -4) to 12 weeks post randomization in non-diabetic subjects with low HDL-C and metabolic syndrome. After baseline, all subjects titrated niacin extended release (ER) to 2 grams (g) daily over 4 weeks. Subjects were also given 325 mg aspirin to take 30 minutes before the niacin ER. After 4 weeks, half of the subjects added blinded pioglitazone 30mg/day (milligrams/day) for 6 weeks followed by 45 mg/day for 6 weeks; the other half added placebo. HDL-C was was assessed at baseline and 12 weeks post randomization</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Active Pioglitazone + Open-Label Niacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Pioglitazone, initially 30mg, then titrated to 45mg + niacin ER 2.0 g/day + aspirin 325 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo +Open-Label Niacin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: Pioglitazone Placebo + 2.0 g/day Open-Label Niacin + 325 mg/day Aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone, initially 30 mg, then titrated to 45 mg/day</description>
    <arm_group_label>Active Pioglitazone + Open-Label Niacin</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pioglitazone placebo</description>
    <arm_group_label>Placebo +Open-Label Niacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin ER</intervention_name>
    <description>Niacin ER 2.0 g/day</description>
    <arm_group_label>Active Pioglitazone + Open-Label Niacin</arm_group_label>
    <arm_group_label>Placebo +Open-Label Niacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>asprin 325 mg/day</description>
    <arm_group_label>Active Pioglitazone + Open-Label Niacin</arm_group_label>
    <arm_group_label>Placebo +Open-Label Niacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women between the ages of 18 and 75

          2. HDL-C â‰¤ 40 mg/dL for Men and HDL-C &lt; 50 mg/dl for Women*

          3. At least two of the following criteria (a, b, c, or d) listed below:

               1. Abdominal obesity (waist circumference: men 40 inches and women 35 inches)**

               2. Blood pressure &gt; 130/&gt;85 mmHg in untreated patients OR use of any
                  antihypertensive agent.

               3. Fasting glucose &gt; 100 mg/dL but &lt; 126 mg/dL

               4. Fasting triglycerides &gt; 150 mg/dL

        Exclusion Criteria:

          1. Diabetes or use of anti-hyperglycemic medication in the last 3 months (subjects with a
             fasting blood glucose of &gt; 110 mg/dL will have an oral glucose tolerance test (OGTT)
             to rule out diabetes mellitus).

          2. Subjects on statin therapy may be enrolled, but only if they have been on a stable
             dose for at least 3 months, and are not expected to require titration of statin
             therapy during the course of the study.

          3. Uncontrolled hypertension (defined as systolic bp &gt; 180, diastolic BP &gt; 100).

          4. Triglycerides &gt; 400 mg/dL

          5. LDL-cholesterol level &gt; 190 mg/dl

          6. History of chronic renal insufficiency (serum creatinine &gt;2.0 mg/dl).

          7. History of liver disease or abnormal liver function tests (LFTs) (&gt;2x upper limit
             normal)

          8. Hemoglobin &lt; 10 mg/dL

          9. History of congestive heart failure (NYHA Class III or IV)

         10. Women who are pregnant or lactating

         11. History of a non-skin malignancy within the previous 5 years

         12. Any major active rheumatologic, pulmonary, or dermatologic disease or other chronic
             inflammatory condition

         13. Surgery in the last 90 days

         14. History of HIV positive

         15. Active alcohol or drug abuse

         16. Active peptic ulcer disease

         17. Gout attack within the past 6 months

         18. Participation in an investigational drug study within 6 weeks

         19. Serious or unstable medical or psychological conditions that, in the opinion of the
             investigator, would compromise the subject's safety or successful study participation

         20. Subjects on warfarin may be enrolled, but they will be excluded from the optional
             adipose biopsy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rick Samaha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2006</study_first_submitted>
  <study_first_submitted_qc>March 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2006</study_first_posted>
  <results_first_submitted>April 4, 2017</results_first_submitted>
  <results_first_submitted_qc>June 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 28, 2017</results_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HDL cholesterol</keyword>
  <keyword>Metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited and participated in the study from December 2005 and July 2007. Subjects were recruited from the University of Pennsylvania and the Philadelphia Veterans Affairs Medical Center.</recruitment_details>
      <pre_assignment_details>4 weeks prior to randomization, subjects titrated to 2.0 g/day of niacin extended release. Subjects who could not tolerate niacin were excluded from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pioglitazone Placebo + Open-Label Niacin + Aspirin</title>
          <description>Subjects receiving pioglitazone placebo in combination with niacin ER 2.0 g/daily and aspirin 325 mg</description>
        </group>
        <group group_id="P2">
          <title>Active Pioglitazone + Open-Label Niacin + Aspirin</title>
          <description>Subjects receiving 45 mg/day active pioglitazone in combination with niacin ER 2.0 g/daily and aspirin 325 mg. Subjects received 30mg/day pioglitazone for 6 weeks, followed by 45 mg/day for another 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pioglitazone Placebo + Open-Label Niacin + Aspirin</title>
          <description>Subjects receiving pioglitazone placebo in combination with niacin ER 2.0 g/daily and 325 mg aspirin</description>
        </group>
        <group group_id="B2">
          <title>Active Pioglitazone + Open-Label Niacin + Asprin</title>
          <description>Subjects receiving 45 mg/day active pioglitazone in combination with niacin ER 2.0 g/daily and 325 mg aspirin. Subjects received 30mg/day pioglitazone for 6 weeks, followed by 45 mg/day for another 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" spread="12.1"/>
                    <measurement group_id="B2" value="49.3" spread="12.2"/>
                    <measurement group_id="B3" value="50.6" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Increase in High Density Lipoprotein Cholesterol (HDL-C) at Baseline and 12 Weeks</title>
        <description>Mean increase in HDL-C from baseline (week -4) to 12 weeks post randomization in non-diabetic subjects with low HDL-C and metabolic syndrome. After baseline, all subjects titrated niacin extended release (ER) to 2 grams (g) daily over 4 weeks. Subjects were also given 325 mg aspirin to take 30 minutes before the niacin ER. After 4 weeks, half of the subjects added blinded pioglitazone 30mg/day (milligrams/day) for 6 weeks followed by 45 mg/day for 6 weeks; the other half added placebo. HDL-C was was assessed at baseline and 12 weeks post randomization</description>
        <time_frame>Baseline, after 12 weeks of pioglitazone vs placebo</time_frame>
        <population>All subjects for whom HDL-C measurements were recorded at baseline (week -4) and 12 weeks post randomization to placebo, niacin ER, and aspirin or pioglitazone, niacin ER, and aspirin</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone Placebo + Open-Label Niacin + Aspirin</title>
            <description>Subjects receiving pioglitazone placebo in combination with niacin ER 2.0 g/daily and 325 mg aspirin</description>
          </group>
          <group group_id="O2">
            <title>Active Pioglitazone + Open-Label Niacin + Asprin</title>
            <description>Subjects receiving 45 mg/day active pioglitazone in combination with niacin ER 2.0 g/daily and 325 mg aspirin. Subjects received 30mg/day pioglitazone for 6 weeks, followed by 45 mg/day for another 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Increase in High Density Lipoprotein Cholesterol (HDL-C) at Baseline and 12 Weeks</title>
          <description>Mean increase in HDL-C from baseline (week -4) to 12 weeks post randomization in non-diabetic subjects with low HDL-C and metabolic syndrome. After baseline, all subjects titrated niacin extended release (ER) to 2 grams (g) daily over 4 weeks. Subjects were also given 325 mg aspirin to take 30 minutes before the niacin ER. After 4 weeks, half of the subjects added blinded pioglitazone 30mg/day (milligrams/day) for 6 weeks followed by 45 mg/day for 6 weeks; the other half added placebo. HDL-C was was assessed at baseline and 12 weeks post randomization</description>
          <population>All subjects for whom HDL-C measurements were recorded at baseline (week -4) and 12 weeks post randomization to placebo, niacin ER, and aspirin or pioglitazone, niacin ER, and aspirin</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4" lower_limit="36.0" upper_limit="38.8"/>
                    <measurement group_id="O2" value="36.2" lower_limit="34.8" upper_limit="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C 12 weeks Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6" lower_limit="38.8" upper_limit="42.6"/>
                    <measurement group_id="O2" value="44.2" lower_limit="42.2" upper_limit="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded from screening (week -4) to completion of study (week 12), for a total of 16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pioglitazone Placebo + Open-Label Niacin + Aspirin</title>
          <description>Subjects receiving pioglitazone placebo in combination with niacin ER 2.0 g/daily and 325 mg aspirin</description>
        </group>
        <group group_id="E2">
          <title>Active Pioglitazone + Open-Label Niacin + Asprin</title>
          <description>Subjects receiving 45 mg/day active pioglitazone in combination with niacin ER 2.0 g/daily and 325 mg aspirin. Subjects received 30mg/day pioglitazone for 6 weeks, followed by 45 mg/day for another 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small Intestinal Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Surgery for Back</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Rectal Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for Shortness of Breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leg Edema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Richard L. Dunbar</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>(215) 315-3378</phone>
      <email>richard.dunbar@uphs.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

